1. Extracorporeal membrane oxygenation for immunocompromised children with acute respiratory distress syndrome: a French referral center cohort
- Author
-
Jean-Eudes Piloquet, Yohan Soreze, Sandrine Jean, Jérôme Rambaud, Pierre-Louis Leger, Isabelle Guellec, Julien Jegard, Julia Guilbert, Julie Starck, Blandine Robert, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU), and Rambaud, Jerome
- Subjects
ARDS ,Pediatrics ,medicine.medical_specialty ,medicine.medical_treatment ,Extracorporeal ,Extracorporeal Membrane Oxygenation ,children ,Intensive care ,Extracorporeal membrane oxygenation ,medicine ,Humans ,Child ,Survival rate ,Referral and Consultation ,Retrospective Studies ,Respiratory Distress Syndrome ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,business.industry ,medicine.disease ,veno-arterial ECMO ,3. Good health ,immunocompromised ,Respiratory failure ,Life support ,Cohort ,Pediatrics, Perinatology and Child Health ,Quality of Life ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,veno-venous ECMO - Abstract
International audience; Background: Immunocompromised children are likely to develop a refractory acute respiratory distress syndrome (ARDS). The usefulness of providing extracorporeal life support (ECLS) to these patients is a subject of debate. The aim of our study was to report the outcomes and to compare factors associated with mortality between immunocompromised and non-immunocompromised children supported with veno-venous ECMO. Methods: We performed a retrospective monocentric study in the French pediatric ECMO center of Armand Trousseau Hospital, including all pediatric patients aged from 1 month to 18 years requiring ECLS for ARDS. Results: Between 2007 and 2018, one hundred and eleven (111) patients underwent ECMO for respiratory failure; among them twenty-five (25) were immunocompromised. Survival rate at 6 months after intensive care discharge was significantly lower for immunocompromised patients compared to non-immunocompromised ones (41.7% vs. 62.8%; p = 0.04). ARDS severity was similar between the 2 groups. Fungal pneumonias were reported only in immunocompromised patients (12.5% versus 0% in the control group; p = 0.001). Bleeding complications were significantly more frequent in the immunocompromised group and blood product transfusions were also more frequently required in this group. Conclusion: Six months after intensive care discharge, survival rate of immunocompromised children supported with ECMO for pediatric ARDS is lower than for nonimmunocompromised patients. But, the expectation for a favorable outcome is real and it is worth it if their condition is likely to be compatible with a good long-term quality of life.
- Published
- 2022
- Full Text
- View/download PDF